Hospitalization and 90-day all-cause mortality rates and RRs for individuals with CLL, by CLL treatment status and SARS-CoV-2 variant period
| Variable . | COVID-19 hospitalization . | 90-day all-cause mortality . | ||||
|---|---|---|---|---|---|---|
| Hospitalization rate % (n/N) . | Unadjusted RR (95% CI) . | Adjusted RR (95% CI) . | Mortality rate % (n/N) . | Unadjusted RR (95% CI) . | Adjusted RR (95% CI) . | |
| Bcl-2i, BTKi, or PI3Ki∗ | ||||||
| Not treated | 42.6 (435/1022) | Ref | Ref | 14.5 (148/1022) | Ref | Ref |
| Treated | 49.8 (133/267) | 1.17 (1.02-1.35) | 1.25 (1.02-1.54) | 16.9 (45/267) | 1.16 (0.86-1.58) | 1.56 (1.03-2.37) |
| Corticosteroids† | ||||||
| Not treated | 42.4 (488/1150) | Ref | Ref | 13.8 (159/1150) | Ref | Ref |
| Treated | 57.6 (80/139) | 1.36 (1.16-1.59) | 1.23 (1.05-1.44) | 24.5 (34/139) | 1.77 (1.28-2.45) | 1.45 (1.04-2.02) |
| SARS-CoV-2 variant period‡,§ | ||||||
| Wild type | 62.8 (162/258) | Ref | Ref | 24.8 (64/258) | Ref | Ref |
| Alpha | 51.6 (63/122) | 0.82 (0.68-1.00) | 0.85 (0.69-1.04) | 17.2 (21/122) | 0.69 (0.45-1.08) | 0.63 (0.34-1.15) |
| Delta | 42.5 (31/73) | 0.68 (0.51-0.90) | 0.86 (0.60-1.24) | 4.1 (3/73) | 0.17 (0.05-0.51) | 0.14 (0.04-0.47) |
| Omicron | 37.2 (311/835) | 0.59 (0.52-0.67) | 0.62 (0.46-0.84) | 12.6 (105/835) | 0.51 (0.38-0.67) | 0.28 (0.13-0.61) |
| Variable . | COVID-19 hospitalization . | 90-day all-cause mortality . | ||||
|---|---|---|---|---|---|---|
| Hospitalization rate % (n/N) . | Unadjusted RR (95% CI) . | Adjusted RR (95% CI) . | Mortality rate % (n/N) . | Unadjusted RR (95% CI) . | Adjusted RR (95% CI) . | |
| Bcl-2i, BTKi, or PI3Ki∗ | ||||||
| Not treated | 42.6 (435/1022) | Ref | Ref | 14.5 (148/1022) | Ref | Ref |
| Treated | 49.8 (133/267) | 1.17 (1.02-1.35) | 1.25 (1.02-1.54) | 16.9 (45/267) | 1.16 (0.86-1.58) | 1.56 (1.03-2.37) |
| Corticosteroids† | ||||||
| Not treated | 42.4 (488/1150) | Ref | Ref | 13.8 (159/1150) | Ref | Ref |
| Treated | 57.6 (80/139) | 1.36 (1.16-1.59) | 1.23 (1.05-1.44) | 24.5 (34/139) | 1.77 (1.28-2.45) | 1.45 (1.04-2.02) |
| SARS-CoV-2 variant period‡,§ | ||||||
| Wild type | 62.8 (162/258) | Ref | Ref | 24.8 (64/258) | Ref | Ref |
| Alpha | 51.6 (63/122) | 0.82 (0.68-1.00) | 0.85 (0.69-1.04) | 17.2 (21/122) | 0.69 (0.45-1.08) | 0.63 (0.34-1.15) |
| Delta | 42.5 (31/73) | 0.68 (0.51-0.90) | 0.86 (0.60-1.24) | 4.1 (3/73) | 0.17 (0.05-0.51) | 0.14 (0.04-0.47) |
| Omicron | 37.2 (311/835) | 0.59 (0.52-0.67) | 0.62 (0.46-0.84) | 12.6 (105/835) | 0.51 (0.38-0.67) | 0.28 (0.13-0.61) |
Ref, reference.
The adjusted model also included age, residential region, anticoagulant use, immunosuppressive drug use, number of prescribed drugs, time from CLL diagnosis to PCR test, COVID-19 vaccination status, and time since 29 January 2020.
The adjusted model also included age, residential region, anticoagulant use, immunosuppressive drug use, number of prescribed drugs, time from CLL diagnosis to PCR test, COVID-19 vaccination status, and time since 29 January 2020.
The adjusted model also included age, biologic sex, region of birth, residential region, income quartile, anticoagulant use, antidiabetic drug use, antihypertensive drug use, heart disease drug use, immunosuppressive drug use, lipid-modifier use, obstructive lung disease drug use, number of prescribed drugs, time from CLL diagnosis to PCR test, COVID-19 vaccination status, Bcl-2/BTK/PI3K inhibitor use, and corticosteroids use.
One individual with a SARS-CoV-2 Beta variant infection was excluded from these analyses.